检索历史 清除

目的 探讨TFIIB相关因子2(BRF2)蛋白在肝细胞癌(HCC)中的表达及其临床意义.方法 收集2009年11月至2010年1 1月在山东大学齐鲁医院普通外科行根治性肝切除手术治疗的80例HCC患者资料.应用免疫组织化学方法检测HCC癌组织、癌旁组织和正常肝组织中BRF2、CD34(微血管密度)的表达情况.运用统计学方法分析BRF2、CD34表达与临床病理指标的关系.结果 HCC患者癌组织BRF2的高表达率为61.3％,高于正常肝组织及癌旁组织(阳性率分别为31.6％、28.8％,P＜0.05).BRF2与肿瘤分化、结节数目、包膜有无、TNM分期及微血管密度相关.BRF2高表达组预后差:高表达组复发转移率明显高于低表达组(P＜0.05),同时生存率低于低表达组(P＜0.05).结论 BRF2蛋白在HCC患者癌组织表达水平升高,与患者病理指标及预后相关,因此推测BRF2或可用作评价HCC患者预后的指标.

Objective To study the expression of TFIIB-related factor 2 (BRF2) in hepatocellular carcinoma(HCC) and to determine its clinical significance.Methods 80 HCC patients who received ‘curative' hepatectomy at the Qilu Hospital were studied.Immunohistochemistry analysis was performed to examine the expression of BRF2 and CD34 (microvessel density) in tumor tissues,matched paraneoplastic tissues,and normal liver tissues.Statistical methods were performed to analyse the relationships of expressions of BRF2 and CD34 with clinicopathologic factors.Results BRF2 protein was expressed at a high rate of 61.3％ in HCC tumor,which was significantly higher than that in normal liver tissues and matched paraneoplastic tissues (31.6％,28.8 ％,respectively,P ＜ 0.05).BRF2 was significantly associated with tumor differentiation,number of nodules,tumor encapsulation,TNM stage,and microvessel density.Prognosis of the high expression BRF2 group was poor.The recurrence and metastasis rates in the high expression group were significantly higher than the low expression group (P ＜ 0.05).The survival rate in the high expression group was significantly lower than the low expression group (P ＜ 0.05).Conclusions The expression of BRF2 increased in HCC tissues,and its expression was closely associated with pathological features and prognosis of patients,indicating that it can be used as a predictor in assessing prognosis of patients with HCC.